BioPharma Dive May 3, 2024
Updated data show about 75% of treated patients were cancer-free after receiving CG’s therapy, with some showing long-lasting benefits.
Dive Brief:
- An experimental drug from CG Oncology has driven bladder cancers into remission in about three-quarters of people who received it in a Phase 3 trial, matching results the biotechnology company disclosed from a smaller number of study participants last year.
- CG previously said 50 of 66 trial volunteers with non-muscle invasive bladder cancer had no detectable disease after receiving its drug, known as cretostimogene. On Friday, the company presented new data showing 79 of 105 had had complete responses. Additionally, CG said 29 of 35 participants followed for at least 12 months are still cancer-free, though another 22...
Today's Sponsors
Today's Sponsor